-
-
-
-
-
-
-
Verastem (VSTM) PT Lowered to $15 at Jefferies
-
-
-
-
-
-
-
Mizuho Reiterates Outperform Rating on Verastem (VSTM)
-
-
-
-
-
-
-
Cantor Fitzgerald Assumes Verastem (VSTM) at Overweight
-
-
-
-
-
-
-
Verastem publishes phase 2 trial results in Journal of Clinical Oncology
-
-
-
-
-
-
-
Tempus AI (TEM) Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment
-
-
-
-
-
-
-
Jefferies Starts Verastem (VSTM) at Buy
-
-
-
-
-
-
-
Verastem Oncology (VSTM) Appoints Matthew E. Ros as COO
-
412,998 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

